Get started
Author

Swati Khanna

Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD-L1 Antibody Avelumab
2016 · Swati Khanna, Anish Thomas, et al. · Journal of Thoracic Oncology · 108
PDF
Modulation of Extracellular ISG15 Signaling by Pathogens and Viral Effector Proteins
2020 · Caleb D. Swaim, Larissa A. Canadeo, et al. · Cell Reports · 102
Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
2018 · Swati Khanna, Suzanne Graef, et al. · Clinical Cancer Research · 55
PDF
Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
2016 · Jingli Zhang, Swati Khanna, et al. · Clinical Cancer Research · 40
Streptonigrin Inhibits SENP1 and Reduces the Protein Level of Hypoxia-Inducible Factor 1α (HIF1α) in Cells
2018 · Nigus Ambaye, Chih-Hong Chen, et al. · Biochemistry · 28
MT-6402, an engineered toxin body (ETB) targeting PD-L1: Interim efficacy and safety data.
2023 · Minal A. Barve, Brian Andrew Van Tine, et al. · Journal of Clinical Oncology · 2
First-in-human dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data.
2022 · Eugene R Ahn, Herbert Leon Duvivier, et al. · Journal of Clinical Oncology · 2
Abstract 1628: Engineered toxin bodies targeting PD-L1 to alter tumor immunophenotypes and deliver broad antigenic diversity and patient coverage
2021 · Joseph D. Dekker, Swati Khanna, et al. · Cancer Research · 2
Data from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
2023 · Swati Khanna, Suzanne Graef, et al. · 1
884 Engineered toxin body mediated depletion of TIGIT expressing immune cells for cancer immunotherapy
2021 · Elizabeth Saputra, Garrett Cornelison, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
supplementary figure 1 from Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
2023 · Jingli Zhang, Swati Khanna, et al.
Conflict Interest disclosure from Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
2023 · Jingli Zhang, Swati Khanna, et al.
Supplementary figure 1 legend from Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
2023 · Jingli Zhang, Swati Khanna, et al.
Supplementary Figs and Tables from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
2023 · Swati Khanna, Suzanne Graef, et al.
Supplementary figure 1 from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
2023 · Swati Khanna, Suzanne Graef, et al.
PDF
Supplementary figure 2 from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
2023 · Swati Khanna, Suzanne Graef, et al.
PDF
Supplementary figure 4 from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
2023 · Swati Khanna, Suzanne Graef, et al.
Supplementary figure 3 from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
2023 · Swati Khanna, Suzanne Graef, et al.
Data from Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
2023 · Jingli Zhang, Swati Khanna, et al.
Conflict Interest disclosure from Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
2023 · Jingli Zhang, Swati Khanna, et al.
PDF
Supplementary figure 1 from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
2023 · Swati Khanna, Suzanne Graef, et al.
Supplementary figure 3 from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
2023 · Swati Khanna, Suzanne Graef, et al.
PDF
817 Engineered toxin body targeting CTLA-4 (MT-8421) depletes Tregs in the tumor microenvironment and synergizes with αPD-1 to enhance T cell immunity
2022 · Lauren Byrne, Swati Khanna, et al. · Journal for ImmunoTherapy of Cancer
PDF
1379 Engineered toxin body targeting TIGIT depletes Tregs in the tumor microenvironment and reduces tumor burden in mice
2022 · Elizabeth Saputra, Amit Chaudhary, et al. · Journal for ImmunoTherapy of Cancer
PDF
764 First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: interim data
2022 · Brian Van Tine, Eugene Ahn, et al. · Journal for ImmunoTherapy of Cancer
PDF
Works count: 33
Citation count: 341
H-index: 5
I10-index: 5
Year
Topic
Type